Skip to content

Author

C. Wójcik

We have 3 of 15 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real world evaluation of lipoprotein (a) testing and impact on LDL-C management in atherosclerotic cardiovascular disease patients: findings from the CVMOBIUS2 registry

Electronic health record data from 17 US health systems between 1/1/2021-12/31/2024 were analyzed to determine the prevalence of Lp(a) testing among adults with ASCVD and changes in LDL-C management in those who are identified to have elevated Lp(a) levels.

N. Shah, P. Shrader, N. Freeman et al. · 0 citations
Aug 2026

Lipoprotein (a) Testing and Changes in Lipid-Lowering Therapy in Patients With ASCVD: Findings From the cvMOBIUS-2 Registry.

BACKGROUND Although the effectiveness of Lp(a) (lipoprotein[a])-lowering therapies remains under study, lipid guidelines now recommend Lp(a) testing in all adults to identify individuals who need more aggressive risk factor modification. Therefore, we evaluate contemporary patterns of Lp(a) testing and the impact of te...

Nishant P. Shah, P. Shrader, Nikki L. B. Freeman et al. · 0 citations
Open access Aug 2026

Event-Driven Intensification and Persistent Therapeutic Inertia in LDL-C Management Among 1,033,703 Patients With ASCVD

In ASCVD patients, LDL-C levels plateau well above guideline targets following an initial decline, and proactive, system-level monitoring and timely intervention are urgently needed to reduce cumulative above-goal LDL-C exposure.

S. Shoji, P. Shrader, Nikki L. B. Freeman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.